NMDS Group logo

NMDS Group

pdf Publications

Documents

default Use of hematopoietic cell transplantation for patients with myelodysplastic syndrome and chronic myelomonocytic leukemia (21 downloads)
default Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality (131 downloads)
default GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (142 downloads)
default Mutations in histone modulators are associated with prolonged survival during azacitidine therapy (336 downloads)
default Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts (315 downloads)
default Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome (119 downloads)
default Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry (247 downloads)
default SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts (395 downloads)
default High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia (301 downloads)
default Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes (309 downloads)
default Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studie (235 downloads)
default Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study (307 downloads)
default A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome (373 downloads)
default A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine (332 downloads)
default Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo (365 downloads)
pdf Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial (306 downloads)
default Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation (311 downloads)
default Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients (273 downloads)
default Clinical and biological implications of driver mutations in myelodysplastic syndromes (345 downloads)
default Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes (293 downloads)
pdf Evaluation of Azacitidine in transfusion-dependent, Epo-refractory patients with lower-risk MDS ( pdf, 83 KB ) (378 downloads)
pdf Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities (268 downloads)
pdf Significance of JAK2 and TET2 mutations in myelodysplastic syndromes (310 downloads)
pdf Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy (271 downloads)
pdf Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (255 downloads)
pdf Erythropoietin and G-CSF Treatment Associated with Improved Survival in Myelodysplastic Syndrome (313 downloads)
pdf Supportive care, growth factors, and new therapies in myelodysplastic syndromes (280 downloads)
pdf Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome (188 downloads)
pdf Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes (236 downloads)
pdf Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF (275 downloads)
pdf The WHO classification of MDS does make a difference (274 downloads)
pdf No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease (214 downloads)
pdf A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life (238 downloads)